GLP-1 Drug Prescribing Across Scotland Varies Tenfold, ABPI Report Says
GLP-1 prescribing varies across Scotland
NHS prescribing of GLP-1 drugs varies tenfold by location in Scotland, according to a report from the Association of the British Pharmaceutical Industry (ABPI), published on 29 October. The report identifies what it calls “unwarranted variation” in patient access to new medicines.
Why variation matters
Differences in prescribing can mean that access to medicines is not consistent between areas. The report’s finding highlights a potential equity issue for patients and a challenge for health services seeking to apply prescribing decisions consistently.
The information available in the report summary does not provide local prescribing rates, explain the reasons for the tenfold difference, or identify which specific GLP-1 medicines were assessed. Variation alone does not establish why prescribing differs or whether every difference is clinically inappropriate.
What to look for in the full report
- How the report measured prescribing and compared locations.
- Which medicines and patient groups were included.
- Whether local clinical guidance, service capacity, or other factors may help explain the differences.
For further details, consult the full ABPI report and relevant NHS information.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.